New RHD variant alleles

SUMMARY STATEMENT This report describes 22 new RHD variants whose identi-fication was prompted by discrepancies between theresults of targeted genotyping and serology. BACKGROUND The spread of targeted genotyping as a means to confirmserology data or to resolve hematologic discrepancies isaccelerating the discovery of new blood group variants.Listing of blood group variants in public databases inassociation with their phenotype, haplotype, and racialbackground may facilitate decision making by the trans-fusion specialist. BRIEF METHODS Targeted genotyping was performed on BloodChip Refer-encev4.0,anoligonucleotidemicroarraythatinterrogates69 polymorphic positions in the RHD gene (ProgenikaBiopharma, Derio, Spain). Phenotyping was performedby tube, microplate, gel column, solid-phase, andadsorption-elution methods using the following anti-Dreagents (see Table 1): Immuclone RUM-1 (R1), Series 4MS201/MS26 (R2), Gammaclone 401/F8D8 (R3), humanpolyclonal serum (R4), and Novaclone 175-2/D415 1E4(R5) from Immucor; Bioclone MAD2 (R6) and BiocloneD7B8/H1121G6/LORIFA (R7) from Ortho; TH-28 mono-clonal (R8) and ID-Card human polyclonal serum (R9)from Bio-Rad; ESD-1 monoclonal (R10) from DiagnosticsScotland; Albaclone Partial D panel (R11) and AlbacloneWeak D kit (R12) from Alba Bioscience; D-Screen9-monoclonal panel (R13) from Diagast; Albaclone6-monoclonal panel (R14), Albaclone 12-monoclonalpanel(R15),andhumanpolyclonalserum(R16)fromDia-Med. DNA sequencing of